Cyclooxygenases in cancer: progress and perspective.
Aspirin has been used to control pain and inflammation for over a century. Epidemiological studies first associated a decreased incidence of colorectal cancer with the long-term use of aspirin in the early 1980s. Near the same time the first reports showing regression of colorectal adenomas in response to the non-steroidal anti-inflammatory drug (NSAID) sulindac were reported. In subsequent years, the use of other NSAIDs, which inhibit cyclooxygenase (COX) enzymes, was linked to reduced cancer risk in multiple tissues including those of the breast, prostate, and lung. Together these studies resulted in the identification of a new cancer preventive and/or therapeutic target-COX enzymes, especially COX-2. Meanwhile, the overexpression of COX-2, and less consistently, the upstream and downstream enzymes of the prostaglandin synthesis pathway, was demonstrated in multiple cancer types and some pre-neoplastic lesions. Direct interactions of prostaglandins with their receptors through autocrine or paracrine pathways to enhance cellular survival or stimulate angiogenesis have been proposed as the molecular mechanisms underlying the pro-carcinogenic functions of COX-2. The rapid development of safe and effective inhibitors targeting individual COX enzymes not only dramatically improved our understanding of the function of COX-2, but also resulted in discovery of COX independent functions of NSAIDs, providing important hints for future drug design. Here we review the fundamental features of COX enzymes, especially as related to carcinogenesis, their expression and function in both animal tumor models and clinical cancers and the proposed mechanisms behind their roles in cancer.
Zha
Shan
S
Brady Urological Institute, The Johns Hopkins University, Baltimore, MD, USA.
Yegnasubramanian
Vasan
V
Nelson
William G
WG
Isaacs
William B
WB
De Marzo
Angelo M
AM
D000818:Animals; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000201:enzymology*; D011451:Prostaglandin-Endoperoxide Synthases / Q000502:physiology*
D016861:Cyclooxygenase Inhibitors; D011451:Prostaglandin-Endoperoxide Synthases